These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 34059991)
1. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Bernstein DE; Trinh HN; Schiff ER; Smith CI; Mospan AR; Zink RC; Fried MW; Lok AS Dig Dis Sci; 2022 Jun; 67(6):2637-2645. PubMed ID: 34059991 [TBL] [Abstract][Full Text] [Related]
2. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J; Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794 [TBL] [Abstract][Full Text] [Related]
3. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939 [TBL] [Abstract][Full Text] [Related]
4. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B. Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY J Gastroenterol Hepatol; 2024 Aug; 39(8):1673-1683. PubMed ID: 38690711 [TBL] [Abstract][Full Text] [Related]
5. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J; Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety. Chan HLY; Buti M; Lim YS; Agarwal K; Marcellin P; Brunetto M; Chuang WL; Janssen HLA; Fung S; Izumi N; Abdurakhmanov D; Jabłkowski M; Celen MK; Ma X; Caruntu F; Flaherty JF; Abramov F; Wang H; Camus G; Osinusi A; Pan CQ; Shalimar ; Seto WK; Gane E; Am J Gastroenterol; 2024 Mar; 119(3):486-496. PubMed ID: 37561058 [TBL] [Abstract][Full Text] [Related]
7. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. Pan CQ; Chang TT; Bae SH; Brunetto M; Seto WK; Coffin CS; Tan SK; Mo S; Flaherty JF; Gaggar A; Nguyen MH; Çelen MK; Thompson A; Gane EJ PLoS One; 2021; 16(5):e0251552. PubMed ID: 33984038 [TBL] [Abstract][Full Text] [Related]
8. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J; Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593 [TBL] [Abstract][Full Text] [Related]
9. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. Lee IC; Lan KH; Su CW; Li CP; Chao Y; Lin HC; Hou MC; Huang YH Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232631 [TBL] [Abstract][Full Text] [Related]
11. A Real-World Study on Safety and Efficacy of TAF Treatment in HBV Patients with High Risk of Osteoporosis or Osteopenia in China. Li C; Li H; Gong M; Liu Y; Zhang R; Geng J; Wang H; Yu Z; Wang Z; Liu X; Wei J Altern Ther Health Med; 2024 Sep; 30(9):146-151. PubMed ID: 38294749 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B. Liu R; Qiao J; Zhang L; Dou Z Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study. Zhang Q; Xu J; Liu D; Wang L; Ren S; Zheng S; Chen X; Qi L; Lu J Antivir Ther; 2024 Oct; 29(5):13596535241284226. PubMed ID: 39259839 [TBL] [Abstract][Full Text] [Related]
14. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ; J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595 [TBL] [Abstract][Full Text] [Related]
15. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. Buti M; Marcos-Fosch C; Esteban R Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802 [TBL] [Abstract][Full Text] [Related]
16. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir. Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480 [TBL] [Abstract][Full Text] [Related]
17. Comparison of tenofovir alafenamide and entecavir for hepatitis B virus Peng W; Gu H; Jiang C; Liu J; Zhang J; Fu L Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):194-201. PubMed ID: 35545409 [TBL] [Abstract][Full Text] [Related]
18. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597 [TBL] [Abstract][Full Text] [Related]
19. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study. Janssen HLA; Lim YS; Lampertico P; Heo J; Chen CY; Fournier C; Tsang TYO; Bae H; Chen CH; Coffin CS; Ahn SH; Trinh H; Flaherty JF; Abramov F; Zhao Y; Liu Y; Lau A; German P; Chuang WL; Agarwal K; Gane E Lancet Gastroenterol Hepatol; 2024 Aug; 9(8):718-733. PubMed ID: 38901444 [TBL] [Abstract][Full Text] [Related]
20. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. Toyoda H; Leong J; Landis C; Atsukawa M; Watanabe T; Huang DQ; Liu J; Quek SXZ; Ishikawa T; Arai T; Yokohama K; Chuma M; Takaguchi K; Uojima H; Senoo T; Dang H; Maeda M; Hoang J; Le RH; Yasuda S; Thin KN; Tran S; Chien N; Henry L; Asai A; Fukunishi S; Cheung R; Lim SG; Trinh HN; Nguyen MH Hepatology; 2021 Aug; 74(2):656-666. PubMed ID: 33706421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]